Gabapentin Capsule
Product Images NDC 80425-0199

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 80425-0199). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (Description)

Chemical structure diagram of the active ingredient Gabapentin, showing its molecular framework with annotated chemical groups CH2NH2 and CH2CO2H attached to a cyclohexane ring.*

FDA Label Image

Fig 1 (Fig 1)

A line graph showing mean pain score over 8 weeks comparing placebo and Gabapentin 3,600 mg/day. The x-axis represents weeks including a 4-week dose titration and 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 9. Gabapentin shows a decreasing pain score trend compared to placebo.*

FDA Label Image

Label 1 (Lable 1)

Gabapentin 100 mg capsule label from Advanced Rx Pharmacy of Tennessee, LLC. The label includes storage instructions, a comparison note to Neurotin, NDC and lot numbers, expiration date of 10/31/2023, and a barcode. The label shows the packaging location as Nashville, TN.*

FDA Label Image

Label 2 (Lable 2)

Gabapentin 100 mg capsule packaging label from Advanced Rx Pharmacy of Tennessee, LLC. The label includes the product name, strength, dosage form, and a barcode. It notes comparison to Neurontin and provides lot number, expiration date (10/31/2023), and storage conditions (20°-25°C). The label also displays the NDC 80425-0199 and additional pharmacy information.*

FDA Label Image

Fig 2 (Fig 2)

A line graph showing the mean pain score over time in weeks during a 3-week dose titration period followed by a 4-week fixed dose period. It compares placebo with Gabapentin at 1,800 mg/day and 2,400 mg/day doses, illustrating changes in pain scores from baseline to week 7.*

FDA Label Image

Fig 3 (Fig 3)

A bar chart comparing percentage results between placebo (PBO) and gabapentin (GBP) at different dosages in two separate studies. Study 1 shows PBO at 12% and GBP at 29% for 3,600 mg dose. Study 2 displays PBO at 14%, GBP at 32% for 1,800 mg, and GBP at 34% for 2,400 mg doses. Statistical significance is indicated by p-values less than 0.01 and 0.001.*

FDA Label Image

Fig 4 (Fig 4)

A scatter plot chart depicting percentage difference on the vertical axis versus daily dose in milligrams on the horizontal axis. The chart compares three study groups labeled as Study a, Study b, and Study c, each represented by different colored squares. Data points show differences across daily doses ranging from 600 mg to 1,800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.